Cadrenal Therapeutics, Inc. (CVKD)

Cadrenal Therapeutics Statistics

Total Valuation

CVKD has a market cap or net worth of $28.53 million. The enterprise value is $22.73 million.

Market Cap	28.53M
Enterprise Value	22.73M

Important Dates

The next estimated earnings date is Thursday, November 6, 2025, before market open.

Earnings Date	Nov 6, 2025
Ex-Dividend Date	n/a

Share Statistics

CVKD has 2.05 million shares outstanding. The number of shares has increased by 54.78% in one year.

Current Share Class	2.05M
Shares Outstanding	2.05M
Shares Change (YoY)	+54.78%
Shares Change (QoQ)	+6.38%
Owned by Insiders (%)	26.60%
Owned by Institutions (%)	7.33%
Float	1.50M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	6.36
P/TBV Ratio	6.58
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.56

Current Ratio	3.56
Quick Ratio	3.33
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -340.31% and return on invested capital (ROIC) is -216.88%.

Return on Equity (ROE)	-340.31%
Return on Assets (ROA)	-157.41%
Return on Invested Capital (ROIC)	-216.88%
Return on Capital Employed (ROCE)	-334.98%
Revenue Per Employee	n/a
Profits Per Employee	-$3.53M
Employee Count	4
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +15.29% in the last 52 weeks. The beta is 0.99, so CVKD's price volatility has been similar to the market average.

Beta (5Y)	0.99
52-Week Price Change	+15.29%
50-Day Moving Average	12.73
200-Day Moving Average	15.10
Relative Strength Index (RSI)	54.44
Average Volume (20 Days)	28,705

Short Selling Information

The latest short interest is 11,693, so 0.57% of the outstanding shares have been sold short.

Short Interest	11,693
Short Previous Month	11,321
Short % of Shares Out	0.57%
Short % of Float	0.78%
Short Ratio (days to cover)	0.44

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-14.40M
Pretax Income	-14.11M
Net Income	-14.11M
EBITDA	-14.39M
EBIT	-14.40M
Earnings Per Share (EPS)	-$8.62

Balance Sheet

The company has $5.57 million in cash and n/a in debt, giving a net cash position of $5.57 million or $2.72 per share.

Cash & Cash Equivalents	5.57M
Total Debt	n/a
Net Cash	5.57M
Net Cash Per Share	$2.72
Equity (Book Value)	4.30M
Book Value Per Share	2.14
Working Capital	4.29M

Cash Flow

In the last 12 months, operating cash flow was -$11.67 million and capital expenditures -$9,788, giving a free cash flow of -$11.68 million.

Operating Cash Flow	-11.67M
Capital Expenditures	-9,788
Free Cash Flow	-11.68M
FCF Per Share	-$5.70

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

CVKD does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-54.78%
Shareholder Yield	-54.78%
Earnings Yield	-49.85%
FCF Yield	-41.26%

Analyst Forecast

The average price target for CVKD is $32.00, which is 129.56% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$32.00
Price Target Difference	129.56%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	-22.18%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on August 20, 2024. It was a reverse split with a ratio of 1:15.

Last Split Date	Aug 20, 2024
Split Type	Reverse
Split Ratio	1:15

Scores

Altman Z-Score	n/a
Piotroski F-Score	1